Who owns Compass Therapeutics, Inc. (CMPX)? Elite investor 13F holders
2 tracked elite investors reported holding Compass Therapeutics, Inc as of 2026-06-30, including Tudor Investment, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Tudor Investment | Compass Therapeutics Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 197196.00 USD | 90044.000000 | Shares | add | Original filing |
| D.E. Shaw | Compass Therapeutics Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 447827.00 USD | 204487.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.